 Ashoke Khanwalkar
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paranasal Sinuses | 4 | 2023 | 76 | 2.470 |
Why?
| | Nasal Surgical Procedures | 3 | 2023 | 6 | 2.280 |
Why?
| | Tranexamic Acid | 2 | 2023 | 37 | 1.600 |
Why?
| | Rhinitis | 5 | 2024 | 152 | 1.400 |
Why?
| | Endoscopy | 5 | 2024 | 285 | 1.380 |
Why?
| | Lymphatic Abnormalities | 2 | 2020 | 19 | 1.240 |
Why?
| | Sinusitis | 4 | 2024 | 210 | 1.170 |
Why?
| | Nasal Obstruction | 3 | 2022 | 27 | 1.090 |
Why?
| | Nose Diseases | 2 | 2021 | 12 | 0.930 |
Why?
| | Nasal Polyps | 1 | 2024 | 59 | 0.870 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 47 | 0.790 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2022 | 13 | 0.760 |
Why?
| | Biological Products | 1 | 2024 | 202 | 0.720 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 38 | 0.670 |
Why?
| | Neck | 1 | 2020 | 94 | 0.650 |
Why?
| | Hydrocodone | 1 | 2018 | 16 | 0.620 |
Why?
| | Dyspnea | 1 | 2020 | 242 | 0.590 |
Why?
| | Mesothelioma | 2 | 2015 | 38 | 0.590 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 239 | 0.580 |
Why?
| | Postoperative Complications | 2 | 2020 | 2483 | 0.560 |
Why?
| | Betacoronavirus | 1 | 2020 | 249 | 0.550 |
Why?
| | Pain, Postoperative | 1 | 2018 | 233 | 0.520 |
Why?
| | Acetaminophen | 1 | 2018 | 246 | 0.510 |
Why?
| | Inpatients | 1 | 2020 | 467 | 0.500 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 339 | 0.500 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 376 | 0.490 |
Why?
| | Respiration, Artificial | 1 | 2020 | 613 | 0.490 |
Why?
| | Pleural Neoplasms | 1 | 2015 | 24 | 0.490 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 341 | 0.480 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.480 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 373 | 0.480 |
Why?
| | Olfaction Disorders | 3 | 2024 | 60 | 0.460 |
Why?
| | Cystic Fibrosis | 4 | 2024 | 1053 | 0.440 |
Why?
| | Epistaxis | 2 | 2023 | 13 | 0.400 |
Why?
| | Aminophenols | 2 | 2024 | 144 | 0.380 |
Why?
| | Turbinates | 2 | 2022 | 16 | 0.370 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 913 | 0.350 |
Why?
| | Telemedicine | 1 | 2018 | 788 | 0.330 |
Why?
| | Chronic Disease | 5 | 2024 | 1720 | 0.290 |
Why?
| | Smell | 3 | 2024 | 137 | 0.280 |
Why?
| | Humans | 21 | 2024 | 129650 | 0.250 |
Why?
| | Benzodioxoles | 2 | 2024 | 105 | 0.250 |
Why?
| | Treatment Outcome | 5 | 2024 | 10230 | 0.250 |
Why?
| | Drug Combinations | 3 | 2024 | 330 | 0.240 |
Why?
| | Omalizumab | 1 | 2024 | 50 | 0.220 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 13 | 0.220 |
Why?
| | Indoles | 2 | 2024 | 387 | 0.220 |
Why?
| | Quality of Life | 4 | 2023 | 2704 | 0.210 |
Why?
| | Platelet-Rich Plasma | 1 | 2022 | 32 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2344 | 0.200 |
Why?
| | Blood Loss, Surgical | 1 | 2023 | 93 | 0.200 |
Why?
| | Cautery | 1 | 2022 | 4 | 0.190 |
Why?
| | Bevacizumab | 1 | 2022 | 129 | 0.180 |
Why?
| | Prospective Studies | 6 | 2024 | 7133 | 0.180 |
Why?
| | Vibration | 1 | 2021 | 69 | 0.180 |
Why?
| | Nasal Cavity | 1 | 2021 | 51 | 0.180 |
Why?
| | Rhinoplasty | 1 | 2021 | 27 | 0.180 |
Why?
| | Seroma | 1 | 2020 | 3 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 759 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 530 | 0.160 |
Why?
| | Return to Work | 1 | 2018 | 19 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2018 | 29 | 0.150 |
Why?
| | Hypersensitivity | 1 | 2022 | 249 | 0.150 |
Why?
| | Double-Blind Method | 1 | 2023 | 1876 | 0.150 |
Why?
| | Retrospective Studies | 3 | 2020 | 14518 | 0.140 |
Why?
| | Operative Time | 1 | 2018 | 124 | 0.140 |
Why?
| | Tumor Burden | 2 | 2015 | 286 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 151 | 0.130 |
Why?
| | Male | 8 | 2024 | 63681 | 0.130 |
Why?
| | Female | 8 | 2024 | 68776 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1368 | 0.120 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 97 | 0.120 |
Why?
| | Middle Aged | 6 | 2024 | 31154 | 0.120 |
Why?
| | Child, Preschool | 2 | 2020 | 10517 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 288 | 0.110 |
Why?
| | Length of Stay | 1 | 2018 | 1127 | 0.100 |
Why?
| | Quinolones | 2 | 2024 | 126 | 0.100 |
Why?
| | Mentors | 1 | 2014 | 178 | 0.100 |
Why?
| | Ambulatory Care Facilities | 1 | 2014 | 228 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1488 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 176 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4897 | 0.090 |
Why?
| | Pyridines | 2 | 2024 | 478 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6556 | 0.080 |
Why?
| | Students, Medical | 1 | 2014 | 316 | 0.080 |
Why?
| | Child | 2 | 2020 | 20883 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5406 | 0.080 |
Why?
| | Adult | 5 | 2024 | 35576 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2535 | 0.080 |
Why?
| | Clinical Competence | 1 | 2014 | 1017 | 0.070 |
Why?
| | Infant | 1 | 2020 | 9024 | 0.060 |
Why?
| | Aged | 3 | 2021 | 22103 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 9765 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2023 | 67 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 257 | 0.050 |
Why?
| | Nose | 1 | 2022 | 63 | 0.050 |
Why?
| | Ribs | 1 | 2021 | 33 | 0.050 |
Why?
| | Patient Health Questionnaire | 1 | 2021 | 36 | 0.040 |
Why?
| | Adolescent | 1 | 2020 | 20393 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 405 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 341 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 329 | 0.040 |
Why?
| | Cadaver | 1 | 2021 | 306 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 278 | 0.040 |
Why?
| | Cartilage | 1 | 2021 | 180 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 616 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 1968 | 0.040 |
Why?
| | Young Adult | 2 | 2024 | 12426 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7086 | 0.030 |
Why?
| | Volunteers | 1 | 2014 | 30 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 320 | 0.030 |
Why?
| | Animals | 1 | 2015 | 35361 | 0.030 |
Why?
| | Peer Group | 1 | 2014 | 225 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1295 | 0.020 |
Why?
| | Interpersonal Relations | 1 | 2014 | 392 | 0.020 |
Why?
| | Program Evaluation | 1 | 2014 | 875 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1988 | 0.020 |
Why?
|
|
Khanwalkar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|